Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia

Journal of Investigative Medicine

Volumn 52, Issue 3, 2004, Pages 177-184

  Van Tits, Lambertus J H ^a   Smilde, Tineke J ^a   Van Wissen, Sanne ^b   De Graaf, Jacqueline ^a   Kastelein, John J P ^b   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Familial hypercholesterolemia; Low density lipoprotein properties; Statins

Indexed keywords

ALKADIENE; ATORVASTATIN; AUTOANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD LEVEL; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATION; RANDOMIZED CONTROLLED TRIAL; THICKNESS;

EID: 3042722185     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-52-03-32     Document Type: Article

References (53)

1. Slack J. Risk of ischemic heart disease in familial hyperlipoproteinemic states. Lancet 1969;ii:1380-2.
2. Simon Broome Register Group. Risk of fatal coronary artery disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893-6.
3. Austin MA, Breslow JL, Hennekes CH, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
4. Swinkels DW, Demacker PNM, Hendriks JCM, van't Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis 1989;9:604-13.
5. Campos H, Genest JJ Jr, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscl Thromb 1992;12:187-95.
6. De Graaf J, Demacker PNM, Stalenhoef AFH. The effect of simvastatin on the low-density lipoprotein subfraction profile and its composition in familial hypercholesterolemia. Neth J Med 1993;43:254-61.
7. Hoogerbrugge N, Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density cholesterol concentration in male but not in female patients with familial hypercholesterolemia. Atherosclerosis 1999;146:167-74.
8. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res 1982;23:97-104.
9. Swinkels DW, Hak-Lemmers HLM, Demacker PNM. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. J Lipid Res 1987;28:1233-9.
10. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscl Thromb Vasc Biol 1997;17:3542-56.
11. Griffin BA, Caslake MJ, Yip B, et al. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59-67.
12. De Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscl Thromb Vasc Biol 1991;11:298-306.
13. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low-density lipoprotein subfractions of differing density and particle size. Atheroslcerosis 1992;93:189-99.
14. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominant in combined hyperlipidemia. J Lipid Res 1993;34:295-308.
15. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic phenotype, pattern-B. Am J Med 1993;94:350-6.
16. Salonen JT, Yla Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
17. Lehtimaki T, Lehtinen S, Solakivi S, et al. Autoantibodies against oxidized low-density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscl Thromb Vasc Biol 1999;19:23-7.
18. Campos H, Arnolds KS, Balestra ME, et al. Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 1996;16:794-801.
19. De Graaf J, Hendriks JCM, Swinkels DW, et al. Differences in LDL receptor-mediated metabolism of three low-density lipoprotein subfractions by human monocyte-derived macrophages: impact on the risk for atherosclerosis. Artery 1993;20:201-30.
20. Deckelbaum RJ, Eisenberg S, Oschry Y, et al. Reversible modification of human plasma low-density lipoprotiens toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J Biol Chem 1982;257:6509-17.
21. Austin MA, Krauss RM. Genetic control of low-density lipoprotein subclasses. Lancet 1986;ii:592-5.
22. De Graaf J, Swinkels DW, de Haan AFJ, et al. Both inherited susceptibility and environmental exposure determine the low-density lipoprotein subfraction pattern distribution in healthy Dutch families. Am J Hum Genet 1992;51:1295-310.
23. Bredie SJH, Kiemeney LA, deHaan AFJ, et al. Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet 1996;58:812-22.
24. Smilde TJ, Trip MD, Wollersheim H, et al. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima-media thickness in patients with familial hypercholesterolemia. Clin Drug Invest 2000;20:67-79.
25. Smilde TJ, van Wissen H, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia: a randomised trial. Lancet 2001;357:577-81.
26. Demacker PNM, Hessels M, Toenhake-Dijkstra H, Baadenhuijsen H. Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample to reagent ratio. Clin Chem 1997;43:663-8.
27. Stalenhoef AFH, de Graaf J, Wittekoek ME, et al. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low-density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 2000;153:129-38.
28. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vivo oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75.
29. Kleinveld HA, Hak-Lemmers HL, Stalenhoef AFH, Demacker PNM. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992;38:2066-72.
30. Van Tits L, de Waart F, Hak-Lemmers HL, et al. Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radic Biol Med 2001;30:1122-9.
31. Smilde TJ, Wollersheim H, Van Langen H, Stalenhoef AFH. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci 1997;93:317-24.
32. McNamara JR, Jenner JL, Zhengling L, et al. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb Vasc Biol 1992;12:1284-90.
33. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-53.
34. Tan CE, Foster L, Caslake MJ, et al. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler Thromb Vasc Biol 1995;15:1839-48.
35. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959-64.
36. Van den Akker JM, Bredie SJH, Diepenveen SHA, et al. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16:238-44.
37. Raal FJ, Areias AJ, Waisberg R, von Arb M. Susceptibility of low-density lipoprotein to oxidation in familial hypercholesterolemia. Atherosclerosis 1995;115:9-15.
38. Raal FJ, Picher GJ, Waisberg R, et al. Low-density lipoprotein cholesterol bulk is the pivotel, determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol 1999;83:1330-33.
39. Kleinveld HA, Demacker PN, de Haan AF, Stalenhoef AF. Decreased in vitro oxidizability, of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl CoA reductase inhibitors. Eur J Clin Invest 1993;23:289-95.
40. Oranje WA, Sels J-PJE, Rondas-Colbers GJWM, et al. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 2001;311:91-4.
41. Kontush A, Hubner C, Finckh B, et al. How different constituents of low density lipoprotein determine its oxidizability by copper: a correlational approach. Free Radic Res 1996;24:135-47.
42. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991;11:1245-9.
43. Bots ML, Hoes AW, Koudstraal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-7.
44. Chambless LE, Heis G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerotic Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-94.
45. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9.
46. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
47. Hodis HN, Mack WL, Labree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. A randomized, controlled clinical trial. Ann Intern Med 1996;124:548-56.
48. Kroon AA, Van Asten WNJC, Stalenhoef AFH. Effects of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-54.
49. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-8.
50. Furberg CD, Adams HP, Applegate WB, et al, for the Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87.
51. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.
52. Skoglund-Andersson C, Tang R, Bond G, et al. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol 1999;19:2422-30.
53. De Sauvage Nolting PRW, Twickler MB, Dalling-Thie GM, et al. Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy. Circulation 2002;106:788-92.